Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
- 1Division of Vascular Surgery, Hamamatsu Medical Center, Hamamatsu, Shizuoka, Japan.
- 2Division of Vascular Surgery, Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
Abstract
Most distal deep vein thrombosis (DVT) presents a low risk of central progression and pulmonary thromboembolism (PTE), and uniform anticoagulation is not recommended. However, the perioperative period of hip fracture (HF) is associated with a high risk of DVT progression, but a therapeutic dose of anticoagulation raises concern about bleeding risk. There is no clear recommendation for anticoagulation for asymptomatic distal DVT during the perioperative period of HF. We retrospectively evaluated the appropriateness of general anticoagulant prophylaxis with edoxaban. From April 2017 to September 2022, among patients who underwent HF surgery at our hospital, 74 consecutive cases who were diagnosed with asymptomatic distal DVT were examined. Of the 52 cases receiving anticoagulant prophylaxis with edoxaban, 23 received the prophylactic standard dose (30 mg), and 29 received the prophylactic lower dose (15 mg). The duration of anticoagulation ranged from 5 to 28 days, with a median of 14 days. There were no recurrences of symptomatic venous thromboembolism (VTE) within 3 months after starting anticoagulation. This study suggests that a general perioperative prophylactic dose, rather than a therapeutic dose, can effectively suppress symptomatic VTE and enhance safety in patients with asymptomatic distal DVT developed during the perioperative period of HF. (This is a translation of Jpn J Phlebol 2025; 36: 33-38.).
Related
- Less is more: reconsidering asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae screening for gay, bisexual and other men who have sex with men in the era of doxycycline post-exposure prophylaxis (DoxyPEP)
- CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY
- Impact of direct oral anticoagulant treatment on management and outcomes of patients with hip fractures by monitoring assays. A population-based study of a cohort from the Geriatric Perioperative Unit
- Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study
- CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
BibTeX
@article{ishikawa2026anticoagulant,
title = {{Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.}},
author = {Nozomu Ishikawa and Naoto Yamamoto and Tatsuro Yata and Takafumi Kayama and Yuta Yamanaka and Kazunori Inuzuka and Masaki Sano and Kazuto Katahashi and Hajime Tsuyuki and Yusuke Endo and Hiroya Takeuchi and Naoki Unno},
journal = {Annals of vascular diseases},
year = {2026},
month = oct,
doi = {10.3400/avd.oa.26-00179},
url = {https://europepmc.org/article/MED/42953902},
note = {CC BY},
}
RIS
TY - JOUR
TI - Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
AU - Nozomu Ishikawa
AU - Naoto Yamamoto
AU - Tatsuro Yata
AU - Takafumi Kayama
AU - Yuta Yamanaka
AU - Kazunori Inuzuka
AU - Masaki Sano
AU - Kazuto Katahashi
AU - Hajime Tsuyuki
AU - Yusuke Endo
AU - Hiroya Takeuchi
AU - Naoki Unno
PY - 2026
DA - 2026/10/27
JO - Annals of vascular diseases
DO - 10.3400/avd.oa.26-00179
UR - https://europepmc.org/article/MED/42953902
AB - Most distal deep vein thrombosis (DVT) presents a low risk of central progression and pulmonary thromboembolism (PTE), and uniform anticoagulation is not recommended. However, the perioperative period of hip fracture (HF) is associated with a high risk of DVT progression, but a therapeutic dose of anticoagulation raises concern about bleeding risk. There is no clear recommendation for anticoagulation for asymptomatic distal DVT during the perioperative period of HF. We retrospectively evaluated the appropriateness of general anticoagulant prophylaxis with edoxaban. From April 2017 to September 2022, among patients who underwent HF surgery at our hospital, 74 consecutive cases who were diagnosed with asymptomatic distal DVT were examined. Of the 52 cases receiving anticoagulant prophylaxis with edoxaban, 23 received the prophylactic standard dose (30 mg), and 29 received the prophylactic lower dose (15 mg). The duration of anticoagulation ranged from 5 to 28 days, with a median of 14 days. There were no recurrences of symptomatic venous thromboembolism (VTE) within 3 months after starting anticoagulation. This study suggests that a general perioperative prophylactic dose, rather than a therapeutic dose, can effectively suppress symptomatic VTE and enhance safety in patients with asymptomatic distal DVT developed during the perioperative period of HF. (This is a translation of Jpn J Phlebol 2025; 36: 33-38.).
SN - 1881-641X
SN - 1881-6428
ER -